Linked Life Data

19233066

Source:http://linkedlifedata.com/resource/pubmed/id/19233066

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2009-2-23
pubmed:abstractText
The vast majority of patients with chronic kidney disease (CKD) receive an erythropoietic-stimulating agent (ESA) to partially correct the almost inevitable anemia associated with renal insufficiency. However, a minority of CKD patients will require much higher than usual doses of ESA in order to maintain a reasonable hemoglobin concentration. In many instances, these patients will have either an obvious or a clinically unapparent inflammatory process to account for the hyporesponsiveness to ESA replacement therapy. This review focuses on the mechanisms by which inflammation interferes with erythroid marrow function and particularly the new information about the role of inflammatory cytokines and the small peptide, hepcidin, on altered iron metabolism.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1548-5609
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
16
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
76-82
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Hyporesponsiveness to erythropoiesis stimulating agents in chronic kidney disease: the many faces of inflammation.
pubmed:affiliation
Division of Hematology/Oncology, University of California at San Diego, VA Medical Center, San Diego, CA 92161, USA. john.adamson2@va.gov
pubmed:publicationType
Journal Article, Review